688177 百奥泰
午间休市 08-26 11:29:58
资讯
新帖
简况
股市必读：百奥泰新发布《百奥泰 2026年半年度报告摘要》
证券之星 · 09:24
股市必读：百奥泰新发布《百奥泰 2026年半年度报告摘要》
图解百奥泰中报：第二季度单季净利润同比下降216.87%
证券之星 · 01:48
图解百奥泰中报：第二季度单季净利润同比下降216.87%
每周股票复盘：百奥泰（688177）普贝希获肝细胞癌新适应症批准
证券之星 · 08-23
每周股票复盘：百奥泰（688177）普贝希获肝细胞癌新适应症批准
百奥泰（688177）披露贝伐珠单抗注射液新增肝细胞癌适应症获批，8月21日股价下跌4.78%
证券之星 · 08-21
百奥泰（688177）披露贝伐珠单抗注射液新增肝细胞癌适应症获批，8月21日股价下跌4.78%
中东制药巨头与百奥泰签署合作协议
投资观察 · 08-18
中东制药巨头与百奥泰签署合作协议
【机构调研记录】华夏基金调研百奥泰、福瑞医科
证券之星 · 08-11
【机构调研记录】华夏基金调研百奥泰、福瑞医科
每周股票复盘：百奥泰（688177）上半年预亏2.3亿至2.9亿元
证券之星 · 08-02
每周股票复盘：百奥泰（688177）上半年预亏2.3亿至2.9亿元
百奥泰半年再亏近3亿 创新药“烧钱”模式遭遇资金大考
新浪证券 · 07-31
百奥泰半年再亏近3亿 创新药“烧钱”模式遭遇资金大考
股市必读：新发布《百奥泰 自愿披露关于与Intas Pharmaceuticals Ltd.就BAT2506（戈利木单抗）注射液签署授权许可与商业化协议收到里程碑付款的进展公告》
证券之星 · 07-31
股市必读：新发布《百奥泰 自愿披露关于与Intas Pharmaceuticals Ltd.就BAT2506（戈利木单抗）注射液签署授权许可与商业化协议收到里程碑付款的进展公告》
百奥泰：收到BAT2506授权许可里程碑付款225万美元
格隆汇 · 07-29
百奥泰：收到BAT2506授权许可里程碑付款225万美元
百奥泰（688177）披露2026年半年度业绩预告，7月28日股价下跌0.82%
证券之星 · 07-28
百奥泰（688177）披露2026年半年度业绩预告，7月28日股价下跌0.82%
百奥泰：预计2026年1-6月扣非后净利润亏损2.4亿元至3亿元
证券之星 · 07-28
百奥泰：预计2026年1-6月扣非后净利润亏损2.4亿元至3亿元
百奥泰最新公告：预计2026年半年度净亏损2.30亿元-2.90亿元
证券之星 · 07-28
百奥泰最新公告：预计2026年半年度净亏损2.30亿元-2.90亿元
百奥泰(688177.SH)发预亏，预计半年度归母净亏损2.3亿元到2.9亿元
智通财经 · 07-28
百奥泰(688177.SH)发预亏，预计半年度归母净亏损2.3亿元到2.9亿元
百奥泰宣布其靶向CD25的抗体药物偶联物Bat8013治疗晚期实体瘤的I期临床研究完成首例患者给药
美股速递 · 07-23
百奥泰宣布其靶向CD25的抗体药物偶联物Bat8013治疗晚期实体瘤的I期临床研究完成首例患者给药
股市必读：百奥泰（688177）7月20日董秘有最新回复
证券之星 · 07-21
股市必读：百奥泰（688177）7月20日董秘有最新回复
每周股票复盘：百奥泰（688177）2025年营收增25.84%
证券之星 · 07-05
每周股票复盘：百奥泰（688177）2025年营收增25.84%
百奥泰的“盈利魔咒”：年入9亿难填20亿巨亏，合规风波再挫出海雄心
新浪证券 · 07-03
百奥泰的“盈利魔咒”：年入9亿难填20亿巨亏，合规风波再挫出海雄心
股市必读：新发布《百奥泰 关于2025年年度报告的信息披露监管问询函的回复公告》
证券之星 · 07-02
股市必读：新发布《百奥泰 关于2025年年度报告的信息披露监管问询函的回复公告》
股市必读：新发布《百奥泰 关于2025年年度报告的信息披露监管问询函的回复公告》
证券之星 · 07-01
股市必读：新发布《百奥泰 关于2025年年度报告的信息披露监管问询函的回复公告》
加载更多
公司概况
公司名称：
百奥泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-02-21
主营业务：
百奥泰生物制药股份有限公司的主营业务是开发创新药和生物类似药。公司的主要产品是格乐立、普贝希、施瑞立、贝塔宁、艾沙力、Gotenfia。
发行价格：
32.76
{"stockData":{"symbol":"688177","market":"SH","secType":"STK","nameCN":"百奥泰","latestPrice":19.38,"timestamp":1787714998000,"preClose":20.14,"halted":0,"volume":3076569,"delay":0,"changeRate":-0.0377,"floatShares":413999999,"shares":413999999,"eps":-1.1085,"marketStatus":"午间休市","change":-0.76,"latestTime":"08-26 11:29:58","open":19.99,"high":20.98,"low":19.33,"amount":60873400,"amplitude":0.0819,"askPrice":19.41,"askSize":4,"bidPrice":19.38,"bidSize":42,"shortable":0,"etf":0,"ttmEps":-1.1085,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787720400000},"marketStatusCode":3,"adr":0,"adjPreClose":20.14,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787707800000,1787715000000],[1787720400000,1787727600000]],"highLimit":22.15,"lowLimit":18.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":414080000,"isCdr":false,"pbRate":37.21,"roa":"--","roe":"--","epsLYR":-0.8,"committee":0.888889,"marketValue":8025000000,"turnoverRate":0.0074,"status":1,"floatMarketCap":8025000000},"requestUrl":"/m/hq/s/688177","defaultTab":"news","newsList":[{"id":"2662669057","title":"股市必读：百奥泰新发布《百奥泰 2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662669057","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662669057?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:24","pubTimestamp":1787707461,"startTime":"0","endTime":"0","summary":"公司公告汇总百奥泰 2026年半年度报告摘要本报告期末总资产为2,574,915,155.83元，较上年度末增长12.57%；归属于上市公司股东的净资产为123,940,544.66元，较上年度末减少67.04%。百奥泰 关于公司2026年度“提质增效重回报”专项行动方案的半年度评估报告2026年上半年，公司研发投入46,844.75万元，同比增长34.30%，占营收比重90.34%。百奥泰 2026年半年度募集资金存放、管理与实际使用情况的专项报告募集资金总额19.656亿元，净额18.762亿元，截至2026年6月30日累计使用18.834亿元，期末余额3927.78万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600016371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662475944","title":"图解百奥泰中报：第二季度单季净利润同比下降216.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662475944","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662475944?lang=zh_cn&edition=full","pubTime":"2026-08-26 01:48","pubTimestamp":1787680085,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰2026年中报显示，上半年度公司主营收入5.19亿元，同比上升17.35%；归母净利润-2.52亿元，同比下降101.68%；扣非净利润-2.54亿元，同比下降48.38%；其中2026年第二季度，公司单季度主营收入2.67亿元，同比上升13.44%；单季度归母净利润-1.0亿元，同比下降216.87%；单季度扣非净利润-1.01亿元，同比下降41.19%；负债率95.19%，投资收益22.98万元，财务费用1221.18万元，毛利率80.5%。财报数据概要请见下图:本文数据来源于百奥泰2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600004290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661214830","title":"每周股票复盘：百奥泰（688177）普贝希获肝细胞癌新适应症批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661214830","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661214830?lang=zh_cn&edition=full","pubTime":"2026-08-23 03:02","pubTimestamp":1787425335,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，百奥泰报收于20.71元，较上周的21.88元下跌5.35%。本周关注点来自公司公告汇总：贝伐珠单抗注射液（普贝希）获批新增用于治疗不可切除肝细胞癌的适应症。截至目前，普贝希已在国内获批六项适应症，并获得中国、美国、欧盟等多个市场上市批准，商业化授权覆盖104个国家和地区。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264687","title":"百奥泰（688177）披露贝伐珠单抗注射液新增肝细胞癌适应症获批，8月21日股价下跌4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661264687?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:23","pubTimestamp":1787307818,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，百奥泰报收于20.71元，较前一交易日下跌4.78%，最新总市值为85.76亿元。百奥泰生物制药股份有限公司近日披露关于贝伐珠单抗注射液（普贝希）获得药品补充申请批准通知书的公告。截至目前，普贝希已在国内获批六项适应症，并获得中国、美国、欧盟等多个市场上市批准，商业化授权覆盖104个国家和地区。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100034181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169580366","title":"中东制药巨头与百奥泰签署合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1169580366","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169580366?lang=zh_cn&edition=full","pubTime":"2026-08-18 13:27","pubTimestamp":1787030851,"startTime":"0","endTime":"0","summary":"8月18日（路透社）——中东制药工业公司SJSC宣布，已与百奥泰正式签订合作协议。根据Avalon Pharma披露的信息，此次合同金额预计低于公司2025财年总收入的5%。自预计的2031年上市日期起，Avalon Pharma预估在合同期内的前7年，累计收入将不少于4亿沙特里亚尔。根据协议条款，百奥泰将继续承担BAT2406的开发、生产及供应职责。这一合作标志着双方在中东地区医药市场的战略布局迈出了关键一步。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658968513","title":"【机构调研记录】华夏基金调研百奥泰、福瑞医科","url":"https://stock-news.laohu8.com/highlight/detail?id=2658968513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658968513?lang=zh_cn&edition=full","pubTime":"2026-08-11 08:14","pubTimestamp":1786407299,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月10日披露的机构调研信息，华夏基金近期对2家上市公司进行了调研，相关名单如下：1）百奥泰 调研纪要：公司已有6款上市药品，其中4款已在欧美获批，预计到2027年下半年共四款产品在欧美上市。2）福瑞医科 调研纪要：公司正探索集团化、批量式投放模式，以降低投放及运营成本。公司计划与基层医疗机构合作，推动肝脏代谢疾病筛查与管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100006085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0113","BK0146","300049","BK0239","688177","BK0114","BK0251","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656319920","title":"每周股票复盘：百奥泰（688177）上半年预亏2.3亿至2.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656319920","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656319920?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:24","pubTimestamp":1785612254,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，百奥泰报收于17.11元，较上周的16.58元上涨3.2%。本周，百奥泰7月27日盘中最高价报17.55元。百奥泰当前最新总市值70.85亿元，在生物制品板块市值排名33/51，在两市A股市值排名2290/5202。本周关注点业绩披露要点：百奥泰预计2026年上半年归属净利润亏损2.3亿元至2.9亿元。公司公告汇总：百奥泰收到Intas支付的225万美元里程碑付款。协议已于2025年2月26日生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655328583","title":"百奥泰半年再亏近3亿 创新药“烧钱”模式遭遇资金大考","url":"https://stock-news.laohu8.com/highlight/detail?id=2655328583","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655328583?lang=zh_cn&edition=full","pubTime":"2026-07-31 13:58","pubTimestamp":1785477480,"startTime":"0","endTime":"0","summary":"根据2026年半年度业绩预告，公司上半年归母净利润预亏2.3亿至2.9亿元，同比增亏最高达1.65亿元。02商业化基本盘承压，造血能力远未形成闭环从已上市产品表现来看，百奥泰的商业化根基尚不稳固。在研发投入持续高强度、核心管线上市推迟、部分产品海外需求波动的多重压力下，百奥泰能否在现金流枯竭前跑通“研发-商业化-自我造血”的正向循环，已成为摆在管理层面前最紧迫的生死命题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-31/doc-iniksnxi0954663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","LNGR","MEDX","06978","BK1574","BK1161","BK0239","688177","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655004078","title":"股市必读：新发布《百奥泰 自愿披露关于与Intas Pharmaceuticals Ltd.就BAT2506（戈利木单抗）注射液签署授权许可与商业化协议收到里程碑付款的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655004078","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655004078?lang=zh_cn&edition=full","pubTime":"2026-07-31 02:45","pubTimestamp":1785437113,"startTime":"0","endTime":"0","summary":"公司公告汇总百奥泰 自愿披露关于与Intas Pharmaceuticals Ltd.就BAT2506注射液签署授权许可与商业化协议收到里程碑付款的进展公告百奥泰生物制药股份有限公司于2025年2月10日与Intas Pharmaceuticals Ltd.签署协议，将BAT2506注射液在美国市场的独占商业化权益有偿许可给Intas，首付款及里程碑款总额最高达1.645亿美元。公司近日收到Intas支付的225万美元里程碑付款。协议已于2025年2月26日生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655286995","title":"百奥泰：收到BAT2506授权许可里程碑付款225万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655286995","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655286995?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:31","pubTimestamp":1785321111,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654883902","title":"百奥泰（688177）披露2026年半年度业绩预告，7月28日股价下跌0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654883902","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654883902?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:39","pubTimestamp":1785249554,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，百奥泰报收于16.99元，较前一交易日下跌0.82%，最新总市值为70.35亿元。该股当日开盘16.9元，最高17.09元，最低16.81元，成交额达4060.55万元，换手率为0.58%。近日，百奥泰生物制药股份有限公司发布2026年半年度业绩预告的自愿性披露公告。营业收入同比增长13.58%到20.37%，主要因格乐立和施瑞立销售额上升，但研发费用同比增长28.67%到40.14%，导致亏损扩大。本次业绩预告未经注册会计师审计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800040120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654003858","title":"百奥泰：预计2026年1-6月扣非后净利润亏损2.4亿元至3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654003858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654003858?lang=zh_cn&edition=full","pubTime":"2026-07-28 18:00","pubTimestamp":1785232835,"startTime":"0","endTime":"0","summary":"证券之星消息，百奥泰发布业绩预告，预计2026年1-6月扣非后净利润亏损2.4亿元至3亿元。费用增长幅度大于营业收入增长幅度，从而导致亏损增加。百奥泰2026年一季报显示，一季度公司主营收入2.52亿元，同比上升21.8%；归母净利润-1.52亿元，同比下降62.68%；扣非净利润-1.53亿元，同比下降53.51%；负债率90.6%，投资收益33.37万元，财务费用630.91万元，毛利率81.34%。本文数据来源于《百奥泰:百奥泰2026年半年度业绩预告的自愿性披露公告》，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800029556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654160070","title":"百奥泰最新公告：预计2026年半年度净亏损2.30亿元-2.90亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654160070","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654160070?lang=zh_cn&edition=full","pubTime":"2026-07-28 17:28","pubTimestamp":1785230896,"startTime":"0","endTime":"0","summary":"百奥泰(688177.SH)公告称，预计2026年半年度归属于母公司所有者的净利润为亏损2.30亿元-2.90亿元。业绩变动主要系研发费用较上年同期增加1.00亿元-1.40亿元，同比增长28.67%-40.14%，费用增长幅度大于营业收入增长幅度，导致亏损增加。注：公司Q2净利润预计亏损0.78亿-亏损1.38亿，Q1净利润-1.52亿，据此计算，Q2净利润预计环比持续亏损。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800028219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654074275","title":"百奥泰(688177.SH)发预亏，预计半年度归母净亏损2.3亿元到2.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654074275","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654074275?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:03","pubTimestamp":1785225797,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)发布公告，公司预计2026年半年度实现归属于母公司所有者的净利润为亏损2.3亿元到2.9亿元，相比上年同期增加亏损1.05亿元到1.65亿元。公司积极拓展市场，阿达木单抗注射液(格乐立®)与托珠单抗注射液(施瑞立®)注射液销售额较上年同期稳步提升。BAT8006、BAT3306等多个研发项目处于关键临床期，研发投入增长比例较大。费用增长幅度大于营业收入增长幅度，从而导致亏损增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"百奥泰(688177.SH)发预亏，预计半年度归母净亏损2.3亿元到2.9亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148013632","title":"百奥泰宣布其靶向CD25的抗体药物偶联物Bat8013治疗晚期实体瘤的I期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1148013632","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148013632?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:49","pubTimestamp":1784810949,"startTime":"0","endTime":"0","summary":"百奥泰（Bio-Thera Solutions, Ltd.）今日宣布，针对晚期实体瘤的新型抗体药物偶联物（ADC）Bat8013，其I期临床试验已成功完成首例患者给药。这款靶向CD25的治疗药物，标志着公司在肿瘤治疗领域的又一重要进展。该临床研究旨在评估Bat8013的安全性、耐受性及初步疗效，为后续研发奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653210793","title":"股市必读：百奥泰（688177）7月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653210793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653210793?lang=zh_cn&edition=full","pubTime":"2026-07-21 01:50","pubTimestamp":1784569823,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，百奥泰报收于17.88元，上涨1.3%，换手率0.94%，成交量3.89万手，成交额6952.53万元。董秘最新回复投资者： 请公司对网站上药物研发管线栏目进行调整，列示相应靶点联合用药的研发进展情况，以方便投资人阅读。交易信息汇总资金流向7月20日主力资金净流出214.52万元，占总成交额0.0%；游资资金净流出174.86万元，占总成交额0.0%；散户资金净流入389.39万元，占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100001474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649269421","title":"每周股票复盘：百奥泰（688177）2025年营收增25.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649269421","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649269421?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:50","pubTimestamp":1783191021,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，百奥泰报收于18.67元，较上周的16.1元上涨15.96%。本周，百奥泰7月3日盘中最高价报18.78元。本周关注点来自业绩披露要点：百奥泰2025年实现营业收入9.35亿元，同比增长25.84%。公司公告汇总立信会计师事务所就百奥泰生物制药股份有限公司2025年年报信息披露监管问询函出具专项说明。公司2025年实现营业收入9.35亿元，同比增长25.84%，归母净亏损3.32亿元，同比减亏1.78亿元。固定资产同比增长110.87%，永和创新产业基地建设推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648527526","title":"百奥泰的“盈利魔咒”：年入9亿难填20亿巨亏，合规风波再挫出海雄心","url":"https://stock-news.laohu8.com/highlight/detail?id=2648527526","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648527526?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:53","pubTimestamp":1783068780,"startTime":"0","endTime":"0","summary":"上市累计亏损超20亿元；核心制剂工厂遭欧盟GMP证书撤销。作为国内生物类似药龙头，百奥泰正同时面临财务可持续性的拷问与国际化合规的严峻挑战。在上交所的年报问询函压力测试下，这家曾以管线数量著称的药企，其“增收不增利”的伤疤被彻底揭开。若无法在短时间内完成整改并通过现场复核，百奥泰不仅将错失欧洲市场的商业化窗口期，更可能波及其在全球其他规范市场的授权与合作布局，令本就脆弱的“出海”逻辑雪上加霜。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-03/doc-inifpkaw2427530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648521948","title":"股市必读：新发布《百奥泰 关于2025年年度报告的信息披露监管问询函的回复公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2648521948","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648521948?lang=zh_cn&edition=full","pubTime":"2026-07-02 05:32","pubTimestamp":1782941536,"startTime":"0","endTime":"0","summary":"公司公告汇总立信会计师事务所关于对百奥泰生物制药股份有限公司2025年年度报告的信息披露监管问询函的专项说明百奥泰生物制药股份有限公司2025年实现营业收入9.35亿元，同比增长25.84%，归母净亏损3.32亿元，同比减亏1.78亿元。百奥泰 关于2025年年度报告的信息披露监管问询函的回复公告百奥泰生物制药股份有限公司就上海证券交易所关于公司2025年年度报告的信息披露监管问询函作出回复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200002364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648561712","title":"股市必读：新发布《百奥泰 关于2025年年度报告的信息披露监管问询函的回复公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2648561712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648561712?lang=zh_cn&edition=full","pubTime":"2026-07-01 04:01","pubTimestamp":1782849688,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，百奥泰报收于16.82元，下跌3.11%，换手率0.85%，成交量3.51万手，成交额5972.61万元。公司公告汇总立信会计师事务所关于对百奥泰生物制药股份有限公司2025年年度报告的信息披露监管问询函的专项说明2025年实现营业收入9.35亿元，同比增长25.84%；归母净亏损3.32亿元，同比减亏1.78亿元。经营活动现金流净流出8,211.17万元，资产负债率上升至83.56%。研发费用为8亿元，年末合同负债及其他非流动资产合计8.55亿元，主要系授权许可款项增加所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100005399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787718520561,"stockEarnings":[{"period":"1week","weight":-0.0289},{"period":"1month","weight":0.2147},{"period":"3month","weight":0.0511},{"period":"6month","weight":-0.1334},{"period":"1year","weight":-0.3839},{"period":"ytd","weight":-0.1296}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.062},{"period":"1year","weight":0.0015},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9768人(较上一季度减少1.31%)","perCapita":"42391股","listingDate":"2020-02-21","address":"广东省广州市黄埔区国际生物岛螺旋二路18号","registeredCapital":"41408万元","survey":" 百奥泰生物制药股份有限公司的主营业务是开发创新药和生物类似药。公司的主要产品是格乐立、普贝希、施瑞立、贝塔宁、艾沙力、Gotenfia。","listedPrice":32.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥泰,688177,百奥泰股票,百奥泰股票老虎,百奥泰股票老虎国际,百奥泰行情,百奥泰股票行情,百奥泰股价,百奥泰股市,百奥泰股票价格,百奥泰股票交易,百奥泰股票购买,百奥泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}